文献速递产科

美国队列中产后药物性血栓预防与静脉血栓栓塞症

Postpartum Pharmacologic Thromboprophylaxis and Venous Thromboembolism in a U.S. Cohort.
PubMed 文献 · Obstet Gynecol · 2025-01-16

这项多中心回顾性队列研究纳入2016至2019年美国四家医院64,886例分娩,评估产后肝素类血栓预防对静脉血栓栓塞症(VTE)及并发症的影响。倾向评分分析显示,预防组与非预防组VTE风险无差异(风险差0.0%,95%CI 0-0.16%),但预防组再入院和伤口并发症风险增加。

要点

  • 产后肝素类血栓预防率13.8%(95%CI 13.5-14.1%),VTE发生率0.11%(95%CI 0.09-0.14%)。
  • 倾向评分分析中,预防组与非预防组VTE风险差0.0%(95%CI 0-0.16%),无差异。
  • 预防组再入院风险差-1.36%(95%CI -2.51至-0.14%),伤口并发症风险差-1.45%(95%CI -2.35至-0.65%),风险增加。

核心结论

  • 在美国队列中,产后药物性血栓预防未降低产后VTE。
  • 结果可能反映尽管调整协变量后仍存在持续混杂,或提示当前血栓预防实践(如剂量、启动时机、使用时长)无效。

研究设计与样本

  • 多中心回顾性队列研究,纳入2016至2019年美国四家医院所有≥20周妊娠分娩者,共64,886例。
  • 排除有VTE个人史或血栓形成倾向、产前诊断VTE或接受治疗性抗凝者。
  • 暴露为产后肝素类药物预防(包括普通肝素和低分子肝素制剂),主要结局为分娩后12周内VTE,次要结局包括再入院和剖宫产术后伤口并发症。
  • 采用增强逆概率治疗加权估计接受预防者的风险差,报告风险差及95%CI。

主要发现

  • 肝素类产后药物血栓预防率为13.8%(95%CI 13.5-14.1%),VTE发生率为0.11%(95%CI 0.09-0.14%)。
  • 接受血栓预防者更可能年龄较大、剖宫产分娩和合并基础疾病。
  • 倾向评分分析中,药物预防与非药物预防相比,VTE风险差0.0%(95%CI 0-0.16%),无差异;再入院风险差-1.36%(95%CI -2.51至-0.14%),伤口并发症风险差-1.45%(95%CI -2.35至-0.65%),风险增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effect of administering postpartum heparin-based pharmacologic thromboprophylaxis on the incidence of postpartum venous thromboembolism (VTE) and complications. METHODS: This was a multicenter retrospective cohort study of all individuals delivering at more than 20 weeks of gestation at four U.S. hospitals from 2016 to 2019. Individuals with a personal history of VTE or thrombophilia, with an antepartum diagnosis of VTE, or receiving therapeutic anticoagulation were excluded. The exposure was postpartum heparin-based pharmacologic prophylaxis (including unfractionated and low-molecular-weight formulations). The primary outcome was VTE identified within 12 weeks of delivery. Secondary outcomes included hospital readmission and wound complications among individuals undergoing cesarean delivery. Baseline characteristics were compared between those receiving and those not receiving pharmacologic thromboprophylaxis. Augmented inverse probability of treatment weighting was used to estimate risk difference in outcomes among those who received prophylaxis. The effects are reported as a risk difference with 95% CIs. Positive and negative effects indicate benefit and harm, respectively. RESULTS: Of 64,886 deliveries included, the rate of heparin-based postpartum pharmacologic thromboprophylaxis was 13.8% (95% CI, 13.5-14.1%), and the rate of VTE was 0.11% (95% CI, 0.09-0.14%). Individuals receiving thromboprophylaxis were more likely to be older, to deliver by cesarean, and to have a comorbid health condition. In propensity score analysis, pharmacologic prophylaxis compared with no pharmacologic prophylaxis resulted in no difference in VTE (risk difference 0.0%, 95% CI, 0-0.16%) but an increased risk for hospital readmission (risk difference -1.36%, 95% CI, -2.51 to -0.14%) and wound complications (risk difference -1.45%, 95% CI, -2.35 to -0.65%). CONCLUSION: Use of postpartum pharmacologic thromboprophylaxis did not reduce postpartum VTE in this U.S. cohort. Findings may reflect persistent confounding despite covariate adjustment or suggest that the current practice of administration of thromboprophylaxis (eg, dosing, timing of initiation, length of use) is ineffective.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bruno AM, Allshouse AA, Saad A, et al. Postpartum Pharmacologic Thromboprophylaxis and Venous Thromboembolism in a U.S. Cohort. Obstet Gynecol. 2025. PMID: 39819867. doi:10.1097/AOG.0000000000005828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。